A post-hoc analysis of censored patients with mHSPC showed benefit with darolutamide, ADT, and docetaxel, supporting primary data from the ARASENS trial.
The phase 3 EVOKE-01 trial did not meet its primary end point of significantly improved OS with sacituzumab govitecan vs docetaxel in pretreated NSCLC.
Researchers have identified a receptor protein known as CHRM1 as a key player in prostate cancer cells' resistance to docetaxel, a commonly used chemotherapy drug to treat advanced cancer that has spread beyond the prostate.